Artivion (NYSE:AORT) Posts Earnings Results

Artivion (NYSE:AORT) released its quarterly earnings results on Thursday. The company reported $0.13 earnings per share (EPS) for the quarter, FiscalAI reports. Artivion had a net margin of 2.55% and a return on equity of 7.15%. The business had revenue of $125.76 million for the quarter, compared to the consensus estimate of $119.99 million.

Here are the key takeaways from Artivion’s conference call:

• Q2 revenue increased 9% year over year to $125.8 million, while adjusted EBITDA rose 7% to $26.4 million. Stent graft revenue accelerated 12% and On-X revenue grew 18%, both despite tougher comparisons.
• Artivion received FDA PMA approval for AMDS in June, removing IRB-related hurdles and expanding permitted marketing claims; management expects adoption and U.S. account conversions to accelerate gradually in the second half rather than through an immediate surge.
• The company completed its Endospan acquisition and plans a full U.S. launch of the FDA-approved NEXUS aortic arch system in January 2027. Management views NEXUS, AMDS, On-X, and the ARTIZEN pipeline as collectively representing roughly $430 million in current U.S. market opportunity.
• Artivion reiterated 2026 guidance for 7%–11% constant-currency revenue growth, or $480 million–$496 million, and adjusted EBITDA of $92 million–$99 million. The outlook assumes minimal NEXUS revenue this year, continued preservation-services timing and supply constraints, and roughly $8 million of Endospan-related expenses.
• Free cash flow was negative $12 million in Q2, while net leverage rose to 3.1 following $150 million of borrowing to fund the Endospan acquisition; the company also expects the $25 million AMDS milestone payment in Q3 and remains exposed to manufacturing and geopolitical risks tied to Endospan’s Israel facility.

Artivion Stock Up 1.4%

Artivion stock traded up $0.37 during mid-day trading on Thursday, reaching $26.54. 1,122,145 shares of the company’s stock were exchanged, compared to its average volume of 560,268. The company has a quick ratio of 2.80, a current ratio of 3.86 and a debt-to-equity ratio of 0.48. Artivion has a twelve month low of $19.16 and a twelve month high of $48.25. The company has a market cap of $1.29 billion, a P/E ratio of 110.60 and a beta of 1.25. The company has a fifty day moving average of $23.42 and a 200-day moving average of $31.16.

Insider Activity at Artivion

In other news, SVP Andrew M. Green sold 44,001 shares of the company’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the sale, the senior vice president owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AORT. Caitong International Asset Management Co. Ltd purchased a new stake in Artivion during the 3rd quarter worth about $27,000. Smartleaf Asset Management LLC grew its position in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Artivion during the fourth quarter worth approximately $79,000. Quadrant Capital Group LLC purchased a new stake in shares of Artivion during the third quarter worth approximately $92,000. Finally, iSAM Funds UK Ltd acquired a new stake in Artivion in the third quarter valued at approximately $131,000. 86.37% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Stifel Nicolaus set a $45.00 target price on shares of Artivion in a report on Monday, June 1st. Citizens Jmp decreased their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating on the stock in a research note on Friday, May 8th. Needham & Company LLC restated a “buy” rating and set a $44.00 price target on shares of Artivion in a research report on Monday, July 20th. LADENBURG THALM/SH SH raised Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a research note on Friday, April 10th. Finally, Citigroup reiterated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Artivion currently has an average rating of “Moderate Buy” and an average price target of $44.17.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.